Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Auro Vaccines is developing a viral vector vaccine for Crimean-Congo hemorrhagic fever (CCHF) using its proprietary VesiculoVax™ platform. This platform utilizes an attenuated recombinant vesicular stomatitis virus (rVSV) as a vector to express antigens from the Crimean-Congo hemorrhagic fever virus (CCHFV). Developed in collaboration with the National Institutes of Health (NIH) and the University of Texas Medical Branch (UTMB), the vaccine aims to stimulate protective immune responses against CCHFV, a widespread tick-borne viral disease with high fatality rates. The vaccine is designed to provide rapid and durable protection against the virus, which is recognized as a significant public health threat.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CCHFV vaccine (Auro Vaccines).